ESR1 and breast carcinoma: A prospective study using MRI demonstrated that uterine changes associated with adjuvant drugs for breast cancer occur exclusively in postmenopausal patients receiving selective estrogen receptor modulators[29]; however, those studies mostly focused on postmenopausal patients.